---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-22-000042"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:15:46.764152+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q2 net sales $771M (+6.6%); cuts FY2022 guidance on FX and COVID decline

## Summary
- Q2 net sales $771.3M (+6.6% reported, +13.1% organic); reported EPS $2.48, adjusted EPS $2.47.
- Proprietary Products segment sales $653.7M (+11.3%, organic +18.3%) led by high-value components and devices.
- Contract-Manufactured Products sales $117.8M (-13.6%, organic -8.9%) on lower diagnostic device component sales.
- FY2022 guidance cut: net sales now $2.950-$2.975B (prior $3.050-$3.075B); adjusted EPS $9.00-$9.15 (prior $9.30-$9.45).
- Guidance reflects $190M FX headwind and ~$85M decline in COVID-19 sales; base business growth partially offsets.

## SEC filing metadata
- accession: 0000105770-22-000042
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577022000042/0000105770-22-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577022000042/wst-20220728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-22-000042
- JSON: https://secwatch.observer/filing/0000105770-22-000042.json
- Plain text: https://secwatch.observer/filing/0000105770-22-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.